Correlation of serum BNP and ET-1 levels with cardiac pump function and ventricular remodeling in patients with heart failure

Limin Qin, Xiaohong Liu, Yi Li*

Department of Cardiology, Affiliated Hospital of Weifang Medical College, Weifang 261031, China

Correspondence to: qilinxin1988@126.com

Received December 27, 2019; Accepted May 17, 2020; Published June 5, 2020

Doi: http://dx.doi.org/10.14715/cmb/2020.66.3.19

Abstract: This study aimed to explore the correlation of serum brain natriuretic peptide (BNP) and endothelin-1 (ET-1) levels with cardiac pump function and ventricular remodeling in patients with heart failure. Eighty-one patients with chronic heart failure admitted to our hospital from March 2016 to November 2018 were enrolled as the study group, and 80 healthy individuals as the control group. Immunofluorescence was used for the detection of serum BNP, ELISA for serum ET-1, and ultrasound for related indexes of cardiac pump function and ventricular remodeling. Moreover, correlation analysis and prognostic factors analysis were carried out. Both BNP and ET-1 were highly expressed in the serum of patients with heart failure. Cardiac pump function related indexes (left atrial ejection fraction (LAEF), left atrial passive ejection fraction (LAPEF), and left atrial active ejection fraction (LAAEF)) in the study group were significantly lower than those in the control group (P< 0.05). While ventricular remodeling related indexes (left ventricular end-diastolic diameter (LVEDD), interventricular septum thickness (IVST), left ventricular posterior wall thickness (LVPM), and left ventricular mass index (LVMI) in the study group were significantly higher than those in the control group (P< 0.05). BNP and ET-1 were negatively correlated with LAEF, LAPEF and LAAEF (P< 0.05), and were positively correlated with LVEDD, IVST, LVPM and LVMI (P< 0.05). The expressions of serum BNP and ET-1 were higher in patients with cardiovascular events than those without cardiovascular events. Hypertension, hyponatremia, high BNP, high ET-1, NYHA classification, decreased LAEF and increased LVEDD were independent risk factors for cardiovascular adverse events. Serum BNP and ET-1 are closely related to cardiac pump function and ventricular remodeling in patients with heart failure and can be used as important reference indexes for prognosis evaluation.

Key words: Heart failure; BNP; ET-1; Cardiac pump function; Ventricular remodeling; Correlation.

Introduction

Chronic heart failure is a common cardiological disease characterized by changes in myocardial structure and cardiac pump function and may occur in patients with terminal cardiac diseases (1, 2). The decreased systolic and diastolic function of the left ventricle is the most important feature of chronic heart failure, which can reduce cardiac output and peripheral circulation blood perfusion, leading to the disorder of internal environment of the body, thus posing a great threat to the life and health of patients (3, 4). Ventricular remodeling, an important outcome in the process of heart failure, is mainly caused by the recurrence of interstitial inflammation, degradation of extracellular matrix and deposition disorder. In clinical practice, the evaluation of the patient’s cardiac function can provide a reference for treatment selection and prognosis evaluation.

As a kind of polypeptide cardiac hormone secreted by ventricles, brain natriuretic peptide (BNP) is a sensitive indicator reflecting the cardiac function with diuretic and vasodilatory effects. Myocardial ischemia, cardiac damage and increased vascular pressure load can stimulate its secretion (6, 7). Endothelin-1 (ET-1) is a neuroendocrine factor derived from vascular endothelium with strong and lasting vascular activity and plays an important role in cardiac fibrosis and ventricular remodeling (8). At present, clinical evaluation of ventricular remodeling and cardiac function is mostly performed by color Doppler ultrasound which accurately assesses cardiac condition but fails to evaluate the overall situation of the organism. So it is not conducive to treatment selection and prognosis evaluation of patients (9, 10).

Therefore, in order to provide more options for the evaluation of cardiac pump function and ventricular remodeling, we analyzed the correlation between them and serum BNP, ET-1 in patients with heart failure.

Materials and Methods

General information

A total of 81 patients with chronic heart failure admitted to our hospital from March 2016 to November 2018 were selected as a study group, including 42 males and 39 females, with an average age of (61.46±5.92) years. Meanwhile, 80 healthy individuals undergoing physical examinations were enrolled as a control group, with an average age of (61.36±5.89) years. Inclusion criteria were as follows: Patients with previous basic
cardiac diseases and diagnosed with chronic heart failure by clinical symptoms and index tests, as well as those with NYHII-IV. Exclusion criteria were as follows: Patients with severe liver and kidney dysfunction, immune system diseases, infectious diseases, malignant tumors, coagulation disorders, cognitive dysfunction and communication disorders, as well as those who did not cooperate with the experiment. All patients and their families agreed to participate in the experiment and signed the informed consent form. This study was approved by the Hospital Ethics Committee.

Detection of serum BNP and ET-1
The patients’ venous blood (5 mL) was sampled on the next day of admission, anticoagulated with EDTA, then centrifuged at 3000r/min to obtain serum. BNP was detected by immunofluorescence (Shenzhen Micropoint Bioscience Co., Ltd., Guangdong mechanical approval No. 20172400048) on an automatic biochemical analyzer (Biosite Company, USA, Triage Meter Plus), while ET-1 was detected by ELISA (Wuhan MSK Biotechnology Co., Ltd., item number: 69-80220). The process was strictly operated in accordance with the kit instructions.

Color Doppler ultrasound
All patients were examined for cardiac function by color Doppler ultrasound (ATL Company, USA, HDI 2300 Color Doppler Echocardiography) within 24 hours after admission, with a probe frequency of 2.0-3.0 MHz. With the patient in a supine position, the cardiac pump function related ultrasonic indexes: left atrial ejection fraction (LAEF), left atrial passive ejection fraction (LAPEF), left atrial active ejection fraction (LAAEF), ventricular remodeling related ultrasonic indexes: left ventricular end-diastolic diameter (LVEDD), inter-ventricular septum thickness (IVST), left ventricular posterior wall thickness (LVPM) were detected respectively. Left ventricular mass index (LVMI) = ventricular weight/body surface area (BSA).

Statistical methods
In this study, the SPSS20.0 (Bizinsight (Beijing) Information Technology Co., Ltd.) was used for statistical analysis. The counting data were analyzed using the chi-squared test, and the measurement data were expressed as mean-standard deviation. t-test was used for comparison between the two groups. GraphPad Prism 6 software was used to visualize the data, and the Pearson test was used for correlation analysis. A value of  P< 0.05 was considered statistically significant.

Results
Comparison of general data
There was no significant difference in gender, age and body mass index (BMI) between the two groups (P> 0.05), indicating comparability (Table 1).

Expression levels of serum BNP and ET-1
The expression levels of BNP and ET-1 in the study group were significantly higher than those in the control group (P< 0.05), as shown in Table 2.

Comparison of related ultrasonic indexes of cardiac pump function and ventricular remodeling
The cardiac pump function related indexes (LAEF, LAPEF, LAAEF) in the study group were significantly

| Factor                  | Study group (n=81) | Control group (n=80) | t/χ² | P     |
|-------------------------|-------------------|----------------------|------|-------|
| Gender                  |                   |                      |      |       |
| Male                    | 42 (51.85)        | 43 (53.75)           | 0.058| 0.809 |
| Female                  | 39 (48.15)        | 37 (46.25)           |      |       |
| Age (years)             |                   |                      |      |       |
| ≤61                     | 34 (41.98)        | 35 (43.75)           | 0.052| 0.820 |
| >61                     | 47 (58.02)        | 45 (56.25)           |      |       |
| BMI (kg/m²)             |                   |                      |      |       |
| ≤22                     | 43 (53.09)        | 42 (52.50)           | 0.006| 0.941 |
| >22                     | 38(46.91)         | 38 (47.50)           |      |       |
| Hypertension            |                   |                      |      |       |
| Yes                     | 31 (83.27)        | 31 (38.75)           | 0.004| 0.950 |
| No                      | 50 (61.73)        | 49 (61.25)           |      |       |
| Alanine aminotransferase (IU/L) | 26.19±1.45 | 26.03±1.41         | 0.055| 0.957 |
| Aspartate aminotransferase (IU/L) | 21.33±1.19 | 21.29±1.16         | 0.216| 0.829 |
| Creatinine (umol/L)     | 64.31±4.39        | 64.02±4.11           | 0.666| 0.433 |
| White blood cell count (×10⁹/L) | 6.61±1.29       | 6.53±1.18           | 0.414| 0.682 |
| Red blood cell count (×10⁹/L) | 4.71±0.45        | 4.67±0.39           | 0.602| 0.548 |
| NYHA classification      |                   |                      |      |       |
| II                      | 29 (35.80)        | -                    |      |       |
| III                     | 30 (37.04)        | -                    |      |       |
| IV                      | 22 (27.16)        | -                    |      |       |

| Index                  | Study group (n=81) | Control group (n=80) | t     | P     |
|------------------------|--------------------|----------------------|-------|-------|
| BNP/(ng·L⁻¹)           | 519.49±41.33       | 96.29±21.38          | 81.45 | < 0.001|
| ET-1/(ng·L⁻¹)          | 89.37±21.57        | 42.74±10.29          | 17.47 | < 0.001|
lower than those in the control group (P < 0.05). Whereas the ventricular remodeling related indexes (LVEDD, IVST, LVPM, LVMI) in the study group were significantly higher than those in the control group (P < 0.05), as shown in Table 3.

**Correlation of BNP and ET-1 with cardiac pump function and ventricular remodeling in patients with heart failure**

BNP was negatively correlated with LAEF, LAPEF and LAAEF (P < 0.05), and was positively correlated with LVEDD, IVST, LVPM and LVMI (P < 0.05). ET-1 was negatively correlated with LAEF, LAPEF and LAAEF (P < 0.05), and was positively correlated with LVEDD, IVST, LVPM and LVMI (P < 0.05), as shown in Table 4 and Figure 1.

**Serum BNP and ET-1 levels in patients with different prognosis**

During the 12-month follow-up, 34 patients suffering from cardiovascular events were considered to have a poor prognosis. Among them, 19 died of cardiac causes and 15 patients were readmitted for heart failure. No cardiovascular events occurred in 47 patients. Comparing the serum BNP and ET-1 levels of all patients, it was found that the levels were significantly higher in patients with cardiovascular events than those without cardiovascular events, and the levels in cardiac death patients were also significantly higher than that in readmitted patients for heart failure (P < 0.05), as shown in Table 5.

**Univariate analysis of poor prognosis in patients with heart failure**

The patients were divided into cardiovascular event group (34 cases) and non-cardiovascular event group (47 cases). Univariate analysis showed that there was

---

Table 3. Comparison of related ultrasonic indexes of cardiac pump function and ventricular remodeling.

| Index          | Study group (n=81) | Control group (n=80) | t     | P      |
|----------------|-------------------|----------------------|-------|--------|
| LAEF%          | 38.93±4.23        | 52.23±7.14           | 14.40 | < 0.001|
| LAPEF%         | 23.85±3.24        | 36.87±5.95           | 17.21 | < 0.001|
| LAAEF%         | 19.45±2.33        | 34.79±4.31           | 28.14 | < 0.001|
| LVEDD(mm)      | 50.04±4.27        | 39.81±5.20           | 13.65 | < 0.001|
| IVST (mm)      | 11.92±1.18        | 9.07±1.03            | 16.32 | < 0.001|
| LVPM (mm)      | 11.37±1.22        | 9.11±1.09            | 12.39 | < 0.001|
| LVMI (mg/g)    | 2.47±0.31         | 1.73±0.11            | 20.13 | < 0.001|

Table 4. Correlation of BNP and ET-1 with cardiac pump function and ventricular remodeling.

| Index          | BNP         | ET-1        |
|----------------|-------------|-------------|
|                | r     | P     | r     | P     |
| LAEF%          | -0.779 | <0.001 | -0.751 | < 0.001|
| LAPEF%         | -0.670 | <0.001 | -0.743 | < 0.001|
| LAAEF%         | -0.766 | <0.001 | -0.716 | < 0.001|
| LVEDD (mm)     | 0.794  | <0.001 | 0.749  | < 0.001|
| IVST (mm)      | 0.615  | <0.001 | 0.633  | < 0.001|
| LVPM (mm)      | 0.721  | <0.001 | 0.632  | < 0.001|
| LVMI (mg/g)    | 0.750  | <0.001 | 0.714  | < 0.001|

Table 5. Serum BNP and ET-1 levels in patients with different prognosis.

| Factor          | Cardiac death group (n=19) | Heart failure group (n=15) | Non-cardiovascular event group (n=47) | F     | P     |
|-----------------|---------------------------|---------------------------|---------------------------------------|-------|-------|
| BNP/(ng·L-1)    | 601.89±45.22              | 520.03±39.53*             | 461.82±34.12**                        | 93.60 | < 0.001|
| ET-1/(ng·L-1)   | 100.17±23.45              | 87.31±19.03*              | 72.91±16.84**                         | 14.73 | < 0.001|

---

Figure 1. Correlation of BNP and ET-1 with cardiac pump function and ventricular remodeling in patients with heart failure; A: BNP was negatively correlated with LAEF (r=-0.779, P< 0.001); B: BNP was negatively correlated with LAPEF (r=-0.670, P< 0.001); C: BNP was negatively correlated with LAAEF (r=-0.766, P< 0.001); D: BNP was positively correlated with LVEDD (r=0.794, P< 0.001); E: BNP was positively correlated with IVST (r=0.615, P< 0.001); F: BNP was positively correlated with LVPM (r = 0.721, P< 0.001); G: BNP was positively correlated with LVMI (r=0.721, P< 0.001); H: ET-1 was negatively correlated with LAEF (r=-0.751, P< 0.001); I: ET-1 was negatively correlated with LAPEF (r=-0.743, P< 0.001); J: ET-1 was negatively correlated with LAAEF (r=-0.716, P< 0.001); K: ET-1 was positively correlated with LVEDD (r=0.749, P< 0.001); L: ET-1 was positively correlated with IVST (r=0.633, P< 0.001); M: ET-1 was positively correlated with LVPM (r=0.632, P< 0.001); N: ET-1 was positively correlated with LVMI (r=0.714, P< 0.001).
Correlation of BNP and ET-1 with cardiac pump function.

Limin Qin et al.

no significant difference in gender, age, BMI, LAEF, IVST, LVPM between the two groups (P> 0.05). While there were significant differences in hypertension, hyponatremia, high BNP, high ET-1, NYHA classification, LAEF, LAPEF, LVEDD and LVMI (P< 0.05) based on Table 6.

**Multivariate analysis of poor prognosis in patients with heart failure**

Hypertension, hyponatremia, high BNP, high ET-1, NYHA classification, LAEF, LAPEF, LVEDD and LVMI were included in the analysis and were assigned as variables (Table 7). The logistic regression model was used to analyze the risk factors of cardiovascular events, and the results showed that hypertension, hyponatremia, high BNP, high ET-1, NYHA classification, decreased LAEF and increased LVEDD were independent risk factors for adverse cardiovascular events (Table 8).

**Table 6.** Univariate analysis of poor prognosis in patients with heart failure.

| Factor                | Cardiovascular event group (n=34) | Non-cardiovascular event group (n=47) | t/χ² | P   |
|-----------------------|----------------------------------|---------------------------------------|------|-----|
| Gender                |                                  |                                       |      |     |
| Male                  | 20 (58.82)                       | 27 (57.45)                            |      |     |
| Female                | 14 (41.18)                       | 20 (42.55)                            |      |     |
| Age (years)           | 61.34±5.86                       | 61.49±5.96                            |      |     |
| BMI (kg/m²)           | 22.87±2.61                       | 22.61±2.58                            |      |     |
| Hypertension          |                                  |                                       |      |     |
| Yes                   | 21 (83.27)                       | 10 (38.75)                            |      |     |
| No                    | 13 (61.73)                       | 37 (61.25)                            |      |     |
| Hyponatremia          |                                  |                                       | 7.124| 0.008|
| Yes                   | 19 (55.88)                       | 39 (82.98)                            |      |     |
| No                    | 15 (44.12)                       | 8 (17.02)                             |      |     |
| BNP/(ng·L⁻¹)          | 572.12±33.16                     | 461.82±34.12                         |      |     |
| ET-1/(ng·L⁻¹)         | 93.12±18.34                     | 72.91±16.84                          |      |     |
| NYHA classification   |                                  |                                       |      |     |
| II ~ III              | 20 (58.82)                       | 39 (82.98)                            |      |     |
| IV                    | 14 (41.18)                       | 8 (17.02)                             |      |     |
| LAEF%                 | 34.28±3.51                       | 39.91±4.01                            |      |     |
| LAPEF%                | 20.28±1.91                       | 26.83±2.14                            |      |     |
| LAAEF%                | 19.34±2.31                       | 19.41±2.34                            |      |     |
| LVEDD (mm)            | 54.61±2.54                       | 45.28±2.12                            |      |     |
| IVST (mm)             | 11.81±1.13                       | 11.75±1.12                            |      |     |
| LVPM (mm)             | 11.72±0.57                       | 11.64±0.62                            |      |     |
| LVMI (mg/g)           | 2.82±0.22                       | 2.23±0.17                             |      |     |

**Table 7.** Assignment table. Hypertension, hyponatremia, high BNP, high ET-1, NYHA classification, LAEF, LAPEF, LVEDD and LVMI were included in the analysis.

| Factor                | Assignment |
|-----------------------|------------|
| Hypertension          | Yes =1, No =2 |
| Hyponatremia          | Yes =1, No =2 |
| BNP                   | >519.49ng·L⁻¹=1, ≤519.49ng·L⁻¹=2 |
| ET-1                  | >89.37ng·L⁻¹=1, ≤89.37ng·L⁻¹=2 |
| LAEF                  | >38.93%=1, ≤38.93 %=2 |
| LAPEF                 | >23.85 %=1, ≤23.85 %=2 |
| LVEDD                 | >50.04mm=1, ≤50.04mm=2 |
| LVMI                  | >2.47mm=1, ≤2.47mm=2 |
| NYHA classification   | II ~ III = 1, IV =2 |

**Table 8.** Multivariate analysis of poor prognosis in patients with heart failure.

| Factor                | β       | S.E  | Wald | OR   | 95%CI         | P     |
|-----------------------|---------|------|------|------|--------------|-------|
| Hypertension          | 0.223   | 0.061| 3.173| 1.231| 1.082~1.403  | < 0.01|
| Hyponatremia          | 0.482   | 0.031| 3.864| 1.617| 1.019~4.195  | 0.032 |
| BNP                   | 0.193   | 0.429| 7.194| 1.226| 1.172~4.391  | < 0.01|
| ET-1                  | 0.343   | 0.239| 2.306| 1.421| 1.719~6.136  | < 0.01|
| LAEF                  | -0.619  | 0.105| 6.465| 0.542| 0.349~0.762  | 0.022 |
| LAPEF                 | -0.081  | 0.155| 0.261| 0.933| 0.681~1.252  | 0.592 |
| LVEDD                 | 0.042   | 0.019| 5.437| 1.039| 1.009~1.087  | 0.021 |
| LVMI                  | 0.161   | 0.142| 1.223| 1.169| 0.891~1.582  | 0.251 |
| NYHA classification   | 0.896   | 0.051| 5.863| 2.422| 1.364~4.639  | 0.031 |
Discussion

Chronic heart failure, one of the common diseases in cardiology, is the end-stage outcome of various cardiac diseases. It mainly characterized by changes in ventricular structure and cardiac pump function, as well as neurohumoral dysfunction and other pathological features (11, 12). As the progress of chronic heart failure, the cardiac pump function gradually declines due to the increase of blood flow resistance caused by the damage of endothelial function (13).

BNP is an active polypeptide secreted by ventricular myocytes, while ET-1 is a vasoactive polypeptide with strong stimulation to vasoconstriction (14, 15). This study aimed to explore the correlation of BNP and ET-1 with cardiac pump function and ventricular remodeling in patients with heart failure. And the results showed that BNP and ET-1 were highly expressed in the serum of patients. At the same time, the related ultrasonic indexes of cardiac pump function and ventricular remodeling were detected. The results found that patients with heart failure showed significantly lower cardiac pump function related indexes (LAEF, LAPEF, LAAEF) but significantly higher ventricular remodeling related indexes (LVEDD, IVST, LVPM and LVMI) than controls. The development of chronic heart failure weakens the cardiac pump function of patients, which in turn increases the burden on ventricles and promotes the synthesis of BNP (16). Therefore, it is clinically believed that changes in BNP expression can evaluate the severity of chronic heart failure (17). A study revealed that elevated ET-1 could increase the expression of various vasoactive substances (18). In addition, another study (19) demonstrated that the expression of ET-1 in patients with heart failure was significantly higher than that in healthy individuals. The above results were consistent with ours.

Then the correlation of BNP and ET-1 with cardiac pump function and ventricular remodeling was further analyzed. The results showed that BNP and ET-1 were negatively correlated with LAEF, LAPEF and LAAEF, and were negatively correlated with LVEDD, IVST, LVPM and LVMI. These suggested that the expressions of BNP and ET-1 reflected the changes in cardiac pump function and ventricular remodeling and evaluated the condition of patients with heart failure. At present, the expression of serum BNP was reported to have a linear relationship with left ventricular end-diastolic pressure and cardiac functional classification. The pathological basis of chronic heart failure is the decrease of cardiac pump function and the deepening of ventricular remodeling. The main manifestation of cardiac pump function decrease is the significant decrease of its ultrasonic indexes (LAEF, LAPEF and LAAEF), and that of the deepening of ventricular remodeling is the increase of its ultrasonic indexes (LVEDD, IVST, LVPM and LVMI). Our results suggested that the increase of BNP and ET-1 was closely related to the decrease of cardiac pump function and the deepening of ventricular remodeling (21-33).

In order to further analyze the correlation between BNP, ET-1 and heart failure, we followed up the patients for 12 months, and divided them into cardiovascular event group and non-cardiovascular event group, and analyzed the influencing factors of cardiovascular events. The results showed that the serum BNP and ET-1 expressions of patients in the cardiovascular event group were significantly higher than those in the non-cardiovascular event group. Moreover, univariate and multivariate analysis indicated that hypertension, hypotension, high BNP, high ET-1, NYHA classification, decreased LAEF and increased LVEDD were independent risk factors for adverse cardiovascular events. In recent years, BNP has been recommended as an effective biological indicator for evaluating the prognosis of patients with heart failure, and its expression is considered to be of great value (34, 35). Another study (36) considered hypotension to be an independent risk factor for severe heart failure death because patients with heart failure complicated with hypotension had a higher in-hospital mortality rate, which was consistent with our conclusion. Besides, our study also suggested that the prognosis of patients with heart failure was related to the decrease of LAEF and the increase of LVEDD. The decreased LAEF represents the decrease of cardiac pump function, and the increased LVEDD represents the deepening of ventricular remodeling, which causes the further aggravation of heart failure in patients, thus leading to poor prognosis (37, 38). There was also a study (39) clearly indicating that LVEDD might be an independent risk factor for cardiac death in patients with heart failure, which was similar to our conclusion.

To sum up, serum BNP and ET-1 are closely related to cardiac pump function and ventricular remodeling in patients with heart failure and can be used as important reference indexes for prognosis evaluation. However, there are also some limitations to this study. Firstly, we did not explore the mechanism of the influence of serum BNP and ET-1 on the cardiac pump function and ventricular remodeling in patients with heart failure, and its internal mechanism was not elaborated either. Secondly, other factors affecting cardiac pump function and ventricular remodeling in patients with heart failure need to be further explored through larger samples and multicenter studies.

Authors’ contributions

LQ conceived the study and drafted the manuscript. LQ designed research; XL performed research; YL contributed new reagents and analytic tools; XL analyzed data. All authors read and approved the final manuscript.

References

1. Testa G, Cacciato F, Bianco A, Della-Morte D, Mazzella F, Galli G, Gargiulo G, Curcio F, Liguori I, Sabusco A, Rengo F. Chronic obstructive pulmonary disease and long-term mortality in elderly subjects with chronic heart failure. Aging Clin Exp Res 2017; 29: 1157-1164.
2. Meijers WC, Velde ARVD, Koboldt ACM, Dijck-Brouwer J, Wu AH, Jaffe A, de-Boer RA. Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur J Heart Fail 2017; 19: 357-365.
3. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hännelmann A, Nilsson B, Møller JE, Hjort J, Rasmussen J, Boesgaard TW. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised,
placebo-controlled trial. Eur J Heart Fail 2017; 19: 69-77.
4. Sutton MSJ, Linde C, Gold MR, Abraham WT, Ghio S, Cerkvenik J, Daubert JC, Reverse Study Group. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization: Results From the REVERSE Trial. Jacc Heart Fail 2017; 5: 169-178.
5. Lottenen-Rakaslehto L, Rissanen R, Gurzeler E, Merentie M, Huusko J, Schneider JE, Liimatainen T, Ylä-Herttuala S. Left ventricular remodeling leads to heart failure in mice with cardiac-specific overexpression of VEGF-B167: echocardiography and magnetic resonance imaging study. Physiol Rep 2017; 5: e13096-e13107.
6. Lucas CM. Stiff left atrial syndrome as another cause for heart failure with preserved ejection fraction and normal BNP levels. Neth Heart J 2017; 25: 224.
7. Kitada S, Kikuchi S, Tsujino T, Masuya T, Ohte N, J-MELODIC study investigators. The prognostic value of brain natriuretic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a sub-analysis of the J-MELODIC study. Esc Heart Fail 2017; 5: 36-45.
8. Zhang X, Cheng HJ, Zhou P, Kitzman DW, Ferrario CM, Li WM, Cheng CP. Cellular basis of angiotensin-(1-7)–induced augmentation of left ventricular functional performance in heart failure. Int J Cardiol 2017; 236: 405-412.
9. Platt MJ, Huber JS, Romanova N, Brunt KR, Simpson JA. Pathophysiological Mapping of Experimental Heart Failure: Left and Right Ventricular Remodeling in Transverse Aortic Constriction Is Temporally, Kinetically and Structurally Distinct. Front Physiol 2018; 9: 472-488.
10. Peng T, Li X, Hu Z, Yang X, Ma C. Predictive role of endothelin in left ventricular remodeling of chronic kidney disease. Ren Fail 2018; 40: 183-186.
11. Bosch L, Csp L, Gong L, Chan SP, Sim D, Yeo D, Jaufeerally K, Lotz J, Hasenfu G, Lücke C, Gutberlet M, Schuler G. Influence of Left Atrial Function on Exercise Capacity and Left Ventricular Function in Patients With Heart Failure and Preserved Ejection Fraction. Circ Cardiovasc Imaging 2017; 10: 5467-5483.
12. Von RM, Rommel KP, Kowallick JT, Blazek S, Besler C, Fengler K, Lotz J, Hassenu F, Lücke C, Gutberlet M, Schuler G. Influence of Left Atrial Function on Exercise Capacity and Left Ventricular Function in Patients With Heart Failure and Preserved Ejection Fraction. Circ Cardiovasc Imaging 2017; 10: 5467-5483.
13. Aronow WS. Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in Older Adults. Heart Fail Clin 2017; 13: 467-483.
14. Khalid U, Wruck ML, Quibrera PM, Agarwal S, Chang PP, Loehr L, Eberle M, Kisman DW, Ferrario CM. Influence of Left Ventricular Function on Exercise Capacity and Left Ventricular Function in Patients With Heart Failure and Preserved Ejection Fraction. Circ Cardiovasc Imaging 2017; 10: 5467-5483.
15. Dzudic A, Dzekem BS, Kengne AP. NT-pro BNP and plasma-soluble ST2 as promising biomarkers for hypertension, hypertensive heart disease and heart failure in sub-Saharan Africa. Cardiovasc J Afr 2017; 28: 406-407.
16. McMurray JJ, Adamopoulos S, Anker SD. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 20121 of the European Society of Cardiology Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
17. Das BB. Plasma B-type natriuretic peptide in children with cardiovascular diseases. Pediat Cardiol 2010; 31(8): 1135-45.
18. Zhang CL, Xie S, Qiao X, An YM, Zhang Y, Li L, Guo XB, Zhang FC, Wu LL. Plasma endothelin-1-related peptides as the prognostic biomarkers for heart failure: A PRISMA-compliant meta-analysis. Medicine 2017; 96: e9342-e9352.
19. Karmazyn M. Chapter 3 – Endothelin-1 as a Cardiac-Derived Autocrine, Paracrine and Intracrine Factor in Heart Health and Disease. Endocrine Heart Health Dis 2017; 59-85.
20. Udelsin JE, Konstam MA. Ventricular remodeling fundamental to the progression (and regression) of heart failure. J Am Coll Cardiol 2011; 57: 1477-479.
21. He Q, Huang Y. Correlation of serum MR-ProANP and NT-ProBNP content with pump function and ventricular remodeling in patients with left heart failure. J Hainan Med Univ (English Edition) 2017; 23(2): 65-9.
22. Huang Y, Qiu J, Lu J, Lei H, Wei M, Qiu G. Changes of plasma nt-proBNP and MMP-2 levels and relationship with left ventricular remodeling in patients treated by pravastatin with chf after PCI therapy for AMI. J Shanghai Jiaotong Univ (Med Sci) 2010; 30(3): 336-339.
23. Liang Y, Lin Q, Huang P, Wang Y, Li J, Zhang L, Cao J. Rice Bioactive Peptide Binding with TLR4 To Overcome H2O2-Induced Injury in Human Umbilical Vein Endothelial Cells through NF-κB Signaling. J Agri Food Chem 2018; 66(2): 440-448.
24. Wang L, Lin Q, Yang T, Liang Y, Nie Y, Luo Y, Luo F. Oryzanol modifies high fat diet-induced obesity, liver gene expression profile, and inflammation response in mice. J Agri Food Chem 2017; 65(38): 8374-8385.
25. Lou Y, Shi J, Guo D, Qureshi AK, Song L. Function of PD-L1 in antitumor immunity of glioma cells. Saudi J Biol Sci 2017; 24(4): 803-807.
26. Guo T, Lin Q, Li X, Nie Y, Wang L, Shi L, Luo F. Octacosaanol attenuates inflammation in both RAW264.7 macrophages and a mouse model of colitis. J Agri Food Chem 2017; 65(18): 3647-3658.
27. Li W, Jia MX, Wang JH, Lu JL, Deng J, Tang JX, Liu C. Association of MMP9-1562C/T and MMP13-77A/G polymorphisms with non-small cell lung cancer in southern Chinese population. Biomol 2019; 9(3): 107-119.
28. Nie Y, Luo F, Wang L, Yang T, Shi L, Li X, Shen J, Xu W, Guo T, Lin Q. Anti-hyperlipidemic effect of rice bran polysaccharide and its potential mechanism in high-fat diet mice. Food Funct 2017; 8(11): 4028-4041.
29. Lou Y, Yang J, Wang L, Chen X, Xin X, Liu Y. The clinical efficacy study of treatment to Chiari malformation type I with syringomyelia under the minimally invasive surgery of resection of Submeningeal cerebellar Tonsillar Herniation and reconstruction of Cisterna magna. Saudi J Biol Sci 2019; 26(8): 1927-1931.
30. Lou Y, Guo D, Zhang H, Song L. Effectiveness of mesenchymal stem cells cultured by hanging drop vs. conventional culturing on the repair of hypoxic-ischemic-damaged mouse brains, measured by stemness gene expression. Open Life Sci 2016; 11(1): 519-523.
31. Chen X, Xu Y, Meng L, Chen X, Yuan L, Cai Q, Shi W, Huang G. Non-parametric partial least squares–discriminant analysis model based on sum of ranking difference algorithm for tea grade identification using electronic tongue data identify tea grade using e-tongue data. Sens Actuators B Chem 2020; 311: 1-8.
32. Nie Y, Luo F, Lin Q. Dietary nutrition and gut microflora: A promising target for treating diseases. Trends Food Sci Technol 2018; 75: 72-80.
33. Ren Y, Jiao X, Zhang L. Expression level of fibroblast growth factor 5 (FGF5) in the peripheral blood of primary hypertension and its clinical significance. Saudi J Biol Sci 2018; 25(3): 469-473.
34. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray JJ, Mant J, NICE Guideline Development Group for Acute Heart Failure. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ 2015; 350: 910-925.
35. Balion C, McKeilvie R, Don-Wauchope AC, Santaguida PL, Ore-
Correlation of BNP and ET-1 with cardiac pump function.

Limin Qin et al.  

Mus M, Keshavarz H, Hill SA, Booth RA, Ali U, Brown JA, Bus-tamam A. B-type natriuretic peptide-guided therapy: a systematic review. Heart Fail Rev 2014; 19: 553-564.

36. Baldasseroni S, Urso R, Orso F, Bianchini BP, Carbonieri E, Cirò A, Gonzini L, Leonardi G, Marchionni N, Maggioni AP. Relation between serum sodium levels and prognosis in outpatients with chronic heart failure: neutral effect of treatment with beta-blockers an angiotensin-converting enzyme inhibitors: data from the Italian Network on Congestive Heart Failure (IN-CHF database). J Cardiovasc Med (Hagerstown) 2011; 12: 723-731.

37. Badran HA, Abdelhamid MA, Ibrahim MT, Abdelmoteleb AM, Zarif JK. Left atrium in cardiac resynchronization therapy: Active participant or innocent bystander. J Saudi Heart Assoc 2017; 29: 259-269.

38. Li J, Tang B, Zhang W, Wang C, Yang S, Zhang B, Gao X. Relation and mechanism of Kv2.1 expression to ADH secretion in rats with heart failure. Am J Transl Res 2017; 9: 3687-3695.

39. Kim SH, Kim HJ, Han S, Yoo BS, Choi DJ, Kim JJ, Jeon ES, Cho MC, Chae SC, Ryu KH. The limited prognostic role of echocardiograms in short-term follow-up after acute decompensated heart failure: An analysis of the Korean Heart Failure (KorHF) Registry. Plos One 2017; 12: 1-12.